Payment overview · 2025
General Payments
$890.82
39 reported records · 9 companies
Healthcare provider profile · identity verified
Halis Sonmez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · REGO PARK, NY · NPI 1578792834
Verified facts
What the public records show
CMS Open Payments records show Halis Sonmez, M.D. received $890.82 in general payments during 2025 across 39 reported records.
Amgen Inc. accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Prolia, Rybelsus, Unithroid.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Prolia by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UNITHROID as an associated drug or biological on 7282 records involving 3230 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Unithroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 329 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Rybelsus by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Tymlos by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $204.34 | 22.9% | 10 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $188.46 | 21.2% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $155.69 | 17.5% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $124.20 | 13.9% | 5 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $86.50 | 9.7% | 4 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $49.02 | 5.5% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $38.84 | 4.4% | 2 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $27.93 | 3.1% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $15.84 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $890.82 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $204.34 | 10 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $204.34 | 10 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $188.46 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $155.69 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $155.69 | 7 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $124.20 | 5 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $86.50 | 4 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $49.02 | 2 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $27.93 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 329 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 49 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 146 | exact normalized | Medicare Part D |
| UNITHROID unithroid |
2025 | Unithroid | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
49 | 32 |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | UNITHROID open payments reported associated product |
CMS Open Payments — General Payments 7282 supporting records · 3230 recipient NPIs · example record 1220525525 |
Unithroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
329 | 88 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
146 | 33 |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Mounjaro | Tirzepatide | 440 | 102 |
| Synthroid | Levothyroxine Sodium | 418 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 335 | 114 |
| Ozempic | Semaglutide | 329 | 88 |
| Metformin Hcl Er | Metformin Hcl | 292 | 93 |
| Glipizide Er | Glipizide | 266 | 81 |
| Farxiga | Dapagliflozin Propanediol | 236 | 69 |
| Jardiance | Empagliflozin | 213 | 57 |
| Repaglinide | Repaglinide | 197 | 31 |
| Vascepa | Icosapent Ethyl | 190 | 44 |
| Atorvastatin Calcium | Atorvastatin Calcium | 188 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 187 | 63 |
| Metformin Hcl | Metformin Hcl | 157 | 61 |
| Novolog Flexpen | Insulin Aspart | 151 | 41 |
| Rybelsus | Semaglutide | 146 | 33 |
| Tradjenta | Linagliptin | 143 | 37 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 117 | 34 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 110 | 48 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 102 | 36 |
| Trulicity | Dulaglutide | 102 | 28 |
| Single Use Swab | Alcohol Antiseptic Pads | 100 | 38 |
| Alcohol Pads | Alcohol Antiseptic Pads | 79 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 71 | 33 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 70 | 26 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 70 | 18 |
| Metformin Er Gastric | Metformin Hcl | 65 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 64 | 18 |
| Losartan Potassium | Losartan Potassium | 59 | 19 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 58 | 18 |
| Ezetimibe | Ezetimibe | 57 | 20 |
| Januvia | Sitagliptin Phosphate | 55 | 25 |
| Liothyronine Sodium | Liothyronine Sodium | 52 | 13 |
| Glimepiride | Glimepiride | 51 | 14 |
| Spironolactone | Spironolactone | 50 | 12 |
| Prolia | Denosumab | 49 | 32 |
| Humalog Kwikpen U-100 | Insulin Lispro | 47 | 17 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 46 | 19 |
| Alendronate Sodium | Alendronate Sodium | 44 | 12 |
| Icosapent Ethyl | Icosapent Ethyl | 44 | 14 |
| Lisinopril | Lisinopril | 44 | 18 |
| Dapagliflozin | Dapagliflozin Propanediol | 40 | 16 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 40 | suppressed |
| Methimazole | Methimazole | 39 | 17 |
| Amlodipine Besylate | Amlodipine Besylate | 38 | 13 |
| Cabergoline | Cabergoline | 38 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 26 | 11 |
| Simvastatin | Simvastatin | 26 | suppressed |
| Teriparatide | Teriparatide | 26 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 25 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 21 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 21 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 20 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Glucagon Emergency Kit | Glucagon | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Tymlos | Abaloparatide | 16 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Unithroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $890.82 · 39 records | Amgen Inc. | EVENITY, FREESTYLE LIBRE 3, Omnipod, Ozempic, PROLIA, Rybelsus, UNITHROID, Yorvipath, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error